
The choice of frontline therapy for patients with advanced-stage BRAF-mutant melanoma has been unclear: responses tend to be more familiar with BRAF-targeted treatment but more durable with immune-checkpoint inhibitors (ICIs). Moreover, the initial use of one strategy might affect responses to the other. Now, data from the phase III DREAMseq trial indicate an optimal treatment sequence.
Like
Save
Share